Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Nvision Development, which will manage the operation of the student housing community, is set to break ground on the first ...

More than half of the first phase of the 3.5 GW solar and 4.5 GWh battery storage MTerra Solar project in the Philippines is ...

Marvel’s Phase 5 is shaping up to be a tough chapter for the MCU. Not only has it left fans with a lot of unanswered ...

Adnoc expanding capacity of some of its largest offshore oilfields as part of P5 programme, which aims to ramp up oil ...

Rochester’s $65M outdoor sports complex moves forward with city council approval; construction begins this fall, phase two to ...

An effort to close the project's funding gap died in the Oregon legislature two weeks ago, and now the Trump bill appears to ...

Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...

And menopause itself isn’t the only culprit behind hair shifts as you get older. Other factors linked with aging can affect ...

A GLP-1/glucagon dual agonist conferred weight loss of up to 12.55% at 32 weeks for adults with overweight or obesity, ...